KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Liabilities: 2013-2025

Historic Total Liabilities for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $48.3 million.

  • Xenon Pharmaceuticals' Total Liabilities rose 26.86% to $48.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.3 million, marking a year-over-year increase of 26.86%. This contributed to the annual value of $43.2 million for FY2024, which is 17.24% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Total Liabilities of $48.3 million as of Q3 2025, which was up 19.90% from $40.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Total Liabilities high stood at $48.3 million for Q3 2025, and its period low was $14.4 million during Q1 2021.
  • In the last 3 years, Xenon Pharmaceuticals' Total Liabilities had a median value of $38.4 million in 2023 and averaged $38.5 million.
  • In the last 5 years, Xenon Pharmaceuticals' Total Liabilities plummeted by 70.66% in 2021 and then soared by 103.16% in 2023.
  • Xenon Pharmaceuticals' Total Liabilities (Quarterly) stood at $22.0 million in 2021, then spiked by 48.58% to $32.6 million in 2022, then grew by 12.95% to $36.9 million in 2023, then rose by 17.24% to $43.2 million in 2024, then climbed by 26.86% to $48.3 million in 2025.
  • Its Total Liabilities was $48.3 million in Q3 2025, compared to $40.3 million in Q2 2025 and $39.3 million in Q1 2025.